Methods and compositions relating to microbial treatment and diagnosis of disorders
The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.
1. A method of producing a microbial composition suitable for human consumption, the method comprising:
(a) culturing Akkermansia muciniphila in a culture medium comprising substantially a plant-based culture medium, thereby generating cultured Akkermansia muciniphila ; and
(b) formulating the cultured Akkermansia muciniphila into a unit dosage form, wherein the unit dosage form comprises:
(i) the cultured Akkermansia muciniphila ; and
(ii) a second microbe comprising a 16S rRNA sequence that comprises at least about 97% sequence identity to a 16S rRNA sequence of Eubacterium hallii,
thereby producing the microbial composition suitable for human consumption.
2. The method of claim 1 , wherein the unit dosage form comprises the cultured Akkermansia muciniphila and the second microbe in a powdered form.
3. The method of claim 1 , wherein the unit dosage form comprises the cultured Akkermansia muciniphila and the second microbe in a lyophilized form.
4. The method of claim 3 , wherein the culturing of the Akkermansia muciniphila is carried out anaerobically.
5. The method of claim 1 , wherein the unit dosage form is a capsule.
6. The method of claim 1 , wherein the unit dosage form is a food composition in a form of a bar.
7. The method of claim 1 , wherein the unit dosage form further comprises the plant-based culture medium.
8. The method of claim 7 , wherein the unit dosage form comprises the plant-based culture medium in a powdered form.
9. The method of claim 1 , wherein the unit dosage form comprises at least 1×10 5 CFUs of the cultured Akkermansia muciniphila.
10. The method of claim 1 , wherein the unit dosage form further comprises one or more of: Clostridium beijerinckii, Clostridium butyricum, Clostridium indolis, Bifidobacterium infantis , or Faecalibacterium prausnitzii.
11. The method of claim 1 , wherein the second microbe is Eubacterium hallii.
12. The method of claim 1 , wherein the unit dosage form comprises at least 1×10 5 CFUs of the second microbe.
13. The method of claim 1 , wherein the unit dosage form does not contain dairy.
14. The method of claim 1 , wherein the unit dosage form further comprises Bifidobacterium infantis.
15. The method of claim 1 , wherein the plant-based culture medium comprises an amino acid source that is a plant-protein hydrolysate.
16. The method of claim 1 , wherein the unit dosage form further comprises a prebiotic.
17. The method of claim 1 , wherein the culture medium further comprises one or more vitamins, one or more salts, a buffer, or a combination thereof.
18. The method of claim 1 , wherein the culture medium consists essentially of the plant-based culture medium.
19. The method of claim 1 , wherein the culture medium consists of the plant-based culture medium, one or more salts, one or more vitamins, and a buffer.